SECTION 190.
The division of insurance, in consultation with the bureau of substance abuse services, shall conduct a study of health plan pharmacy and medical benefit design for extended-release injectable naltrexone. The study shall include, but not be limited to, the average time from the issuance of a prescription for extended-release injectable naltrexone to the delivery of the medication and policies to expedite delivery and reduce barriers to patient access in all settings of care. The division and the bureau shall report their findings to the joint committee on mental health and substance abuse and the joint committee on financial services not later than October 1, 2015.